- Home
- ALDX vs TEI Comparison
ALDX vs TEI Comparison
Compare ALDX & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- TEI
- Stock Information
- Founded
- ALDX 2004
- TEI 1993
- Country
- ALDX United States
- TEI United States
- Employees
- ALDX N/A
- TEI N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- TEI Finance Companies
- Sector
- ALDX Health Care
- TEI Finance
- Exchange
- ALDX Nasdaq
- TEI Nasdaq
- Market Cap
- ALDX 270.7M
- TEI 288.6M
- IPO Year
- ALDX 2014
- TEI N/A
- Fundamental
- Price
- ALDX $4.81
- TEI $5.94
- Analyst Decision
- ALDX Strong Buy
- TEI
- Analyst Count
- ALDX 2
- TEI 0
- Target Price
- ALDX $9.50
- TEI N/A
- AVG Volume (30 Days)
- ALDX 1.2M
- TEI 142.4K
- Earning Date
- ALDX 08-12-2025
- TEI 01-01-0001
- Dividend Yield
- ALDX N/A
- TEI 10.51%
- EPS Growth
- ALDX N/A
- TEI N/A
- EPS
- ALDX N/A
- TEI N/A
- Revenue
- ALDX N/A
- TEI N/A
- Revenue This Year
- ALDX N/A
- TEI N/A
- Revenue Next Year
- ALDX $29.89
- TEI N/A
- P/E Ratio
- ALDX N/A
- TEI N/A
- Revenue Growth
- ALDX N/A
- TEI N/A
- 52 Week Low
- ALDX $1.14
- TEI $4.35
- 52 Week High
- ALDX $7.20
- TEI $5.39
- Technical
- Relative Strength Index (RSI)
- ALDX 53.97
- TEI 49.39
- Support Level
- ALDX $5.21
- TEI $5.90
- Resistance Level
- ALDX $5.35
- TEI $5.97
- Average True Range (ATR)
- ALDX 0.33
- TEI 0.08
- MACD
- ALDX -0.12
- TEI -0.02
- Stochastic Oscillator
- ALDX 40.70
- TEI 32.35
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.